Analyst Research

Report Title Price
Provider: Stock Traders Daily
Provider: Stock Traders Daily
Provider: Reuters Investment Profile
Provider: S&P Capital IQ Quantitative Report

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Sarepta Therapeutics Inc Announces Plans To Submit New Drug Application To FDA For Eteplirsen For Treatment Of Duchenne Muscular Dystrophy In First Half Of 2014

Wednesday, 24 Jul 2013 07:00am EDT 

Sarepta Therapeutics, Inc. announced it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2014 for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). Eteplirsen is Sarepta's lead exon-skipping compound in development for the treatment of patients with DMD who have a genotype amenable to skipping of exon 51. 

Company Quote

-0.05 -0.32%
21 Nov 2014